10-Q: Bausch + Lomb Reports Q2 Revenue Growth Amid Operating Loss and Debt Refinancing

Bausch + Lomb announced a 5% increase in second-quarter revenues to $1.278 billion, driven by volume growth and acquisitions, despite an operating loss of $11 million and increased interest expenses following a significant debt refinancing.

Summary

• Total revenues for the three months ended June 30, 2025, increased by $62 million, or 5%, to $1.278 billion, compared to $1.216 billion in the prior year period.
• The revenue increase was primarily driven by a $64 million increase in volumes, a $21 million favorable impact from foreign currencies, and $6 million in incremental sales from acquisitions within the Surgical segment.
• Net realized pricing decreased by $27 million, mainly in the Pharmaceuticals segment, and divestitures/discontinuations reduced revenue by $2 million in the Vision Care segment.
• Operating loss for the quarter was $11 million, a decrease of $37 million from an operating income of $26 million in the same period last year, primarily reflecting higher selling, general, and administrative (SG&A) expenses.
• Net loss attributable to Bausch + Lomb Corporation improved significantly to $62 million for the quarter, compared to a net loss of $151 million in the prior year, largely due to a $161 million favorable change in income taxes.
• Interest expense increased by $26 million to $128 million for the quarter, primarily due to financing costs associated with the June 2025 debt refinancing.
• A loss on extinguishment of debt of $9 million was recorded in the quarter due to the June 2025 refinancing activities.
• For the six months ended June 30, 2025, total revenues grew 4% to $2.415 billion, while the operating loss was $94 million, and net loss attributable to the company was $274 million.
• The Vision Care segment's revenue increased by 8% to $753 million, and segment profit rose by $17 million to $209 million, driven by dry eye portfolio products (Lumify) and contact lenses (SiHy Daily, Ultra, Biotrue).
• The Pharmaceuticals segment's revenue decreased by $1 million to $309 million, and segment profit declined by $41 million to $37 million, impacted by U.S. generics business declines and gross-to-net pricing pressures (XIIDRA), partially offset by MIEBO sales.
• The Surgical segment's revenue increased by 3% to $216 million, but segment profit decreased by $2 million to $2 million, primarily due to the voluntary recall of certain enVista IOL products.
• Cash and cash equivalents and restricted cash decreased by $44 million to $272 million as of June 30, 2025.
• The company completed a debt refinancing on June 26, 2025, establishing a new $800 million revolving credit facility (maturing June 2030) and a new $2.325 billion term B loan facility (maturing January 2031), and issued 675 million EUR Senior Secured Floating Rate Notes due January 2031.
• The proceeds from the refinancing were used to repay the May 2027 Revolving Credit Facility and refinance outstanding term loans due 2027.
• The weighted average stated rate of interest for outstanding debt obligations increased to 8.06% as of June 30, 2025, from 7.95% at December 31, 2024.
• The company acquired Whitecap Biosciences, LLC on January 3, 2025, for approximately $28 million upfront, expensed as acquired in-process research and development costs.
• The voluntary recall of certain enVista IOL products, announced March 27, 2025, was due to raw material issues from a different vendor; the company has since implemented enhanced inspection protocols and returned to full production.
• The company is involved in various legal proceedings, including Shower to Shower product liability litigation (indemnified by Johnson & Johnson), generic pricing antitrust litigation, and Lumify patent proceedings (settlement reached with DRL for June 30, 2027 market entry).
• The last ongoing PreserVision AREDS patent litigation matter was dismissed with prejudice on April 10, 2025.
• The New Mexico Attorney General Consumer Protection Action related to Shower to Shower products was settled, releasing Bausch + Lomb and its affiliates on May 5, 2025.
• The company remains in compliance with its financial covenants related to debt obligations and expects to remain so for the next twelve months.

Sentiment

Score: 5

Explanation: The company shows mixed performance. While revenue growth is positive and the net loss improved significantly due to a tax benefit, the core operating performance deteriorated, and interest expenses increased. The IOL recall impacted the surgical segment. Strategic acquisitions and debt refinancing are positive steps for long-term positioning, but current operational profitability is a concern.

Positives

• Overall revenue growth of 5% for the quarter and 4% for the six months, indicating continued market demand for products.
• Significant improvement in net loss attributable to Bausch + Lomb Corporation, reducing from $151 million to $62 million for the quarter, largely driven by a substantial tax benefit.
• Strong performance in the Vision Care segment, with 8% revenue growth and a 9% increase in segment profit, fueled by dry eye portfolio and contact lenses.
• Successful refinancing of debt, extending maturities and providing financial flexibility, including a new $800 million revolving credit facility and a $2.325 billion term loan.
• Strategic acquisitions like Whitecap Biosciences, Elios Vision, and Trukera Medical are expanding the company's clinical pipeline and market presence in key areas like glaucoma and dry eye.
• Resolution of several legal matters, including the PreserVision AREDS patent litigation and the New Mexico AG consumer protection action, reducing potential liabilities.
• Management's proactive response to the enVista IOL recall, including identifying the root cause (raw material from a different vendor) and implementing enhanced inspection protocols to resume full production.

Negatives

• Operating loss of $11 million for the quarter, a decline from an operating income of $26 million in the prior year, indicating operational challenges despite revenue growth.
• Increased interest expense by $26 million for the quarter, primarily due to financing costs from the recent debt refinancing, impacting profitability.
• The Pharmaceuticals segment experienced a $41 million decrease in segment profit, driven by declines in U.S. generics and pricing pressures on XIIDRA, despite increased sales for MIEBO.
• The Surgical segment's profit decreased by $2 million, directly impacted by the voluntary recall of certain enVista IOL products.
• Cost of goods sold as a percentage of product sales increased to 41.1% from 39.7%, indicating unfavorable product mix and the impact of the enVista IOL recall.
• Selling, general, and administrative (SG&A) expenses increased by $44 million, or 8%, primarily due to higher selling, advertising, and promotion costs for MIEBO.
• Net cash provided by operating activities decreased by $46 million for the six months, partly due to financing fees.
• Net cash used in investing activities increased by $75 million, primarily due to higher capital expenditures.

Risks

• Adverse economic conditions and macroeconomic factors, including heightened inflation and interest rates, slower growth, or a potential recession, could negatively impact revenues, expenses, and margins.
• Risks associated with the voluntary recall of certain enVista IOL products, including the ability to resupply inventory and the success of enhanced inspection protocols.
• Impact of U.S. duty, tariff, and other trading policies, and retaliatory measures by other countries, which could increase manufacturing, distribution, and operational costs.
• Trade conflicts, including current and future disputes between the United States and other countries like China and Canada.
• Challenges associated with managing an independent, complex business following the B+L IPO, including limited transitional services from BHC and potential conflicts of interest due to BHC's ownership.
• Uncertainties and risks associated with the proposed separation from Bausch Health Companies Inc. (BHC), including timing, structure, and potential dis-synergy costs.
• Ongoing litigation and potential additional litigation, claims, and regulatory investigations related to the B+L IPO and the proposed separation from BHC.
• Legislative or policy efforts in the U.S. Congress aimed at reducing patient out-of-pocket costs for medicines, potentially leading to new mandatory rebates, discounts, or pricing restrictions.
• Ongoing oversight and review of products and facilities by regulatory and governmental agencies, including FDA audits, and compliance with legal and regulatory requirements.
• Ability to comply with financial and other covenants in the Amended Credit Agreement and Senior Secured Notes indentures, including limitations on incurring additional debt and making certain payments.
• Any downgrade in credit ratings for Bausch + Lomb or BHC, which could impact the ability to raise debt and the cost of capital.
• Changes in assumptions for impairment analyses, potentially leading to goodwill or intangible asset impairment charges.
• Risks related to acquisitions and business development transactions, including not realizing expected benefits, pipeline products not being commercialized as anticipated, and increased debt levels.
• Uncertainties around the successful improvement and modification of existing products and development of new products, which require significant expenditures and efforts.
• Ability to obtain, maintain, and license sufficient intellectual property rights and defend against challenges to such IP.
• Introduction of generic, biosimilar, or other competitors for branded products, especially those losing patent or regulatory exclusivity.
• Expense, timing, and outcome of pending or future legal and governmental proceedings, arbitrations, investigations, and regulatory matters.
• Ability to obtain components, raw materials, or finished products from third parties, and other manufacturing and supply chain difficulties.
• Potential work stoppages, slowdowns, or other labor problems at facilities.
• Economic factors beyond control, including inflationary pressures, heightened interest rates, and foreign currency fluctuations.
• Risks associated with the ongoing conflict between Russia and Ukraine, and the Middle East conflict, including potential impact on operations, sales, and market conditions.
• Impacts of the new legislation commonly referred to as the 'One Big Beautiful Bill Act' on the company's tax provision.
• Compliance with healthcare fraud and abuse laws, anti-bribery laws, economic sanctions, export laws, environmental laws, and privacy/security regulations.
• Illegal distribution or sale of counterfeit versions of products.
• Interruptions, breakdowns, or breaches in information technology systems.

Future Outlook

The company plans to continue advancing its pipeline of over 60 projects, including new contact lenses for myopia, next-generation cataract equipment, premium IOLs, and investigational treatments for dry eye. Clinical studies are anticipated for dual-action lifitegrast and a first-in-class therapy for ocular surface pain in the second half of 2025. The Lumify next-generation clinical study expects topline results by the end of 2025. The U.S. submission for the ELIOS procedure is being planned. The company expects its primary sources of liquidity to be sufficient for current and future cash needs, and anticipates remaining in compliance with its financial covenants for the next twelve months. The separation from Bausch Health Companies Inc. (BHC) is still being evaluated, with no assurance on its consummation or timing.

Management Comments

• Management believes that completing the separation of the eye health business from BHC makes strategic sense and continues to evaluate all relevant factors and considerations.
• Management believes that the expectations reflected in forward-looking statements are reasonable, but acknowledges risks and uncertainties.
• Management believes that, building on its existing revenue stream from products manufactured in-country, it has certain potential actions to mitigate the overall impact of tariffs, counter-tariffs, and other trade restrictions.
• Management believes the company has a significant innovation opportunity and plans to develop and commercialize its global pipeline of over 60 projects.
• Management believes the company has a well-established product portfolio that is diversified within its core businesses and a robust pipeline that provides for the next generation of existing products and new solutions.
• Management believes that the prosecution of legal actions and counterclaims is important to preserve and protect the company, its reputation, and its assets.
• Management expects to remain in compliance with its financial covenants and meet its debt service obligations over the next twelve months.

Industry Context

Bausch + Lomb operates in the global eye health industry, encompassing vision care, pharmaceuticals, and surgical segments. The company is actively expanding its presence in key growth areas such as dry eye (e.g., MIEBO, XIIDRA, Trukera Medical acquisition) and glaucoma (e.g., Elios Vision acquisition, Whitecap Biosciences acquisition). The voluntary recall of enVista IOLs highlights the regulatory and quality control challenges inherent in the medical device sector. The industry faces ongoing pricing pressures from legislative efforts and generic competition, which the company attempts to manage through aggressive patent defense and pipeline development. Global macroeconomic factors, including inflation, interest rates, and geopolitical conflicts, continue to influence the operating environment.

Comparison to Industry Standards

• NA The filing does not provide specific comparisons to comparable companies, projects, or results within the industry. The focus is on internal performance metrics and strategic initiatives.

Legal Proceedings

• 23 Shower to Shower product liability lawsuits remain pending, with Johnson & Johnson having full indemnification obligations.
• Ongoing multidistrict antitrust litigation (MDL 2724) regarding generic pharmaceuticals pricing, with Bausch Health US and Bausch Health Americas as defendants, and a similar proposed class action in Canada.
• Doctors Allergy Formula, LLC lawsuit against Bausch Health Americas for breach of contract, with trial set for April 2026.
• Lumify Paragraph IV Proceedings against Somerset Therapeutics, LLC and Gland Pharma Limited are ongoing, alleging patent infringement.
• One Notice of Paragraph IV Certification for Vyzulta is under review.
• One Lotemax SM matter resulted in a bench trial, awaiting decision; another matter recently filed and ongoing.

Related Party Transactions

• Bausch Health Companies Inc. (BHC) directly or indirectly holds approximately 88% of Bausch + Lomb's issued and outstanding common shares as of July 23, 2025.
• Amounts payable to BHC and its affiliates related to related party transactions were $8 million as of June 30, 2025, and $5 million as of December 31, 2024.
• Amounts due from BHC and its affiliates related to related party transactions were $11 million as of June 30, 2025, and $25 million as of December 31, 2024.
• Charges incurred related to the Transition Services Agreement (TSA) with BHC were $4 million for the six months ended June 30, 2025, compared to $3 million for the same period in 2024.
• A preliminary settlement with the German taxing authority for the 2014-2016 audit period resulted in an immaterial tax cost, which the company expects to be indemnified by BHC pursuant to the Tax Matters Agreement.

Stakeholder Impact

• Shareholders: Mixed financial results with revenue growth but an operating loss. Net loss improvement is positive but driven by a tax benefit. Debt refinancing provides stability but increases interest expense. The ongoing uncertainty regarding the separation from BHC may impact investor sentiment.
• Employees: Restructuring and integration costs primarily consist of employee severance costs, indicating potential workforce adjustments.
• Customers: The voluntary recall of enVista IOL products may have temporarily impacted customer trust and product availability in the Surgical segment, though the company has resumed full production.
• Suppliers: The enVista IOL recall stemmed from raw material issues from a different vendor, leading to enhanced inspection protocols and more explicit standards for monomer preparation by vendors, potentially impacting supplier relationships and requirements.
• Creditors: The successful debt refinancing and compliance with financial covenants are positive for creditors, indicating the company's ability to manage its debt obligations.

Next Steps

• Initiate a Lumify next-generation clinical study, with topline results expected by the end of 2025.
• Initiate a clinical study for dual-action lifitegrast in the second half of 2025 to address evaporative and inflammatory dry eye.
• Initiate a clinical study for a first-in-class therapy for ocular surface pain in the second half of 2025.
• Initiate a clinical study for the first glaucoma therapy to lower intraocular pressure and improve visual function in the second half of 2025.
• Continue the multi-year study for a Myopia control lens, with a year 1 interim report expected during 2026.
• Plan the U.S. submission of the ELIOS procedure to bolster the glaucoma treatment portfolio.
• Continue European launch of enVista Aspire monofocal and toric IOLs with Intermediate Optimized optics (launched January 2025).
• Continue Canada launch of enVista Aspire monofocal and toric IOLs with Intermediate Optimized optics.
• Continue U.S. and Europe launches of enVista Envy.
• Anticipate U.S. launch of enVista Beyond extended depth of focus (EDOF) IOL early 2027.
• Continue European launch of LuxLife Trifocal IOL with non-Toric and Toric options.
• Monitor the impact of the 'One Big Beautiful Bill Act' on tax provisions for 2025 and future years.
• Continue to evaluate the separation from Bausch Health Companies Inc. (BHC), including its structure and timetable.

Key Dates

Recommendation

Bausch + Lomb's Q2 2025 results present a mixed picture. While revenue growth is encouraging, driven by strong performance in Vision Care and strategic acquisitions, the increase in operating loss and higher interest expenses are notable concerns. The significant improvement in net loss is largely attributable to a one-time tax benefit, which masks underlying operational challenges. The successful debt refinancing is a positive step for managing the company's capital structure and extending maturities. However, the impact of the enVista IOL recall on the Surgical segment and ongoing legal uncertainties warrant a cautious stance. Given the combination of revenue expansion, active portfolio management, and debt restructuring efforts, balanced against operational profitability pressures and external risks, a 'hold' recommendation is appropriate. Investors should monitor the company's ability to translate revenue growth into sustainable operating profits, the full resolution of the IOL recall's impact, and further developments regarding the BHC separation.

Keywords

Eye Health, Ophthalmology, Pharmaceuticals, Vision Care, Surgical Devices, Contact Lenses, Intraocular Lenses, IOL Recall, Debt Refinancing, SEC Filing, 10-Q, Financial Results, Net Loss, Revenue Growth, Acquisitions, R&D, Legal Proceedings, Patent Litigation, SEC Filings, Corporate Debt, Healthcare Industry